Table 4.

Univariate and multivariate analyses for factors at last vaccination associated with developing a vaccine response of HBsAb ≥10 IU/L in participants on HAART at last vaccination (n= 206).

Characteristic	N	Univariate OR (95% CI)	P	Multivariate* OR (95% CI)	P
Age, per 10 year increase	206	0.69 (0.49–0.95)	0.03	0.63 (0.42–0.91)	0.02
Gender
Male	184	Referent		Referent
Female	22	3.11 (1.16–8.29)	0.02	4.85 (1.53–15.38)	0.007
Ethnicity
Caucasian	108	Referent
African American	78	1.11 (0.62–1.99)	0.73
Other	20	0.43 (0.15–1.20)	0.11
BMI, per 1 kg/m2	190	0.99 (0.92–1.06)	0.69
CD4 cell count, per 50 cells/μL increase	199	1.08 (1.02–1.15)	0.01	1.03 (0.96–1.11)	0.36
Nadir CD4 cell count, per 50 cells/μL decrease	203	1.07 (0.99–1.16)	0.12
HIV RNA load, per 1.0 log10 increase	200	0.58 (0.42–0.79)	<0.001	0.60 (0.41–0.88)	0.008
Prior AIDS-defining illness	206	0.32 (0.10–1.03)	0.06
Prior STI	206	1.05 (0.53–2.09)	0.89
Anti-HCV positive	206	0.77 (0.17–3.54)	0.74
Cutaneous DTH
Normal response	129	Referent
Partial response/Anergic	49	0.75 (0.39–1.46)	0.40
No. vaccinations
1–2	60	Referent		Referent
≥3	146	2.25 (1.21–4.20)	0.01	2.40 (1.16–4.98)	0.02

^*The multivariate model was adjusted by era of vaccination (before 1996 versus 1996 or later).

NOTE. All data are prior to or at time of receipt of last dose of vaccine unless otherwise indicated. N, number of participants with data available; OR, odds ratio; CI, confidence interval; BMI, body mass index; STI, sexually transmitted infection; HCV, hepatitis C virus; DTH, delayed-type hypersensitivity; HAART, highly active antiretroviral therapy; vac., vaccination.